Published:
European Company NovaSecta Joins First Chinese CRO Service Alliance for Drug Discovery Solutions
SHANGHAI,China, Feb. 18 /Xinhua-PRNewswire/ -- Today, NovaSecta, Sundia
Meditech and HD BioSciences announced their strategic alliance to provide drug
discovery solutions for European pharmaceutical and biotech companies. This
alliance brings together the high quality scientific capabilities of Sundia
and HD BioSciences with NovaSecta's extensive client base and unique
understanding of European mid-sized pharmaceutical and biotech companies.
To date, the rapidly-growing Chinese Discovery CRO phenomenon has been
largely driven by global and US "Big Pharma" and "Big Biotech" companies --
both as consumers of CRO services and as sources of highly-experienced
returnee scientists toChina. European pharmaceutical and biotech companies
now need to make use of the scientific skills, creative talent pool, flexible
resourcing and cost-effectiveness that many global Big Pharmas already take
for granted inChina.
NovaSecta's business is centered on providing smaller to mid-sized
pharmaceutical and biotech companies the scale advantages that Big Pharmas
enjoy while allowing them to remain independent, fast and flexible. This
alliance is therefore a natural step in NovaSecta's evolution as an R&D
services company. "We selected Sundia Meditech and HD BioSciences as our
alliance partners based on their professionalism and track record in
repeatedly delivering drug discovery solutions to their US and multi-national
clients. Combining the skills and demonstrated drug discovery track record of
their scientific teams with the expertise of European drug discovery
scientists will surely lead to faster and more efficient generation of high
quality drug candidates" said Robert Thong and John Rountree, NovaSecta's co-
founders and Managing Directors.
Sundia Meditech, United PharmaTech, and HD BioSciences entered into a CRO
Service Alliance in May 2007. In the following months, Sundia and United
merged into one company, a first successful merger of China's CRO industry.
The initial alliance was formed to quickly and successfully expand into the
complete range of CRO services to fit the increased demands from clients
worldwide while maintaining high quality and efficiency and minimizing cost.
"We believe that by extending our alliance to include NovaSecta, we will bring
significant benefits to European customers, so we look forward to working with
NovaSecta and more European clients," said Dr. Xiaochuan Wang, Sundia
Meditech's founder and CEO and Dr. Xuehai Tan, HD BioSciences' founder and CEO.
About NovaSecta (http://www.novasecta.com )
NovaSecta is a specialist R&D service provider for smaller to mid-sized
pharmaceutical and biotech companies ('MidPharmas'). Since its founding in
early 2003, NovaSecta has built a unique network of relationships with
MidPharmas inEurope and a deep understanding of how these companies manage
and develop their R&D capabilities. NovaSecta's current business is
originating and managing collaborations for MidPharmas; to date these have
included a multi-company R&D program, product/project licensing and
acquisitions, and scientific R&D collaborations.
About Sundia Meditech (http://www.sundia.com )
Sundia MediTech was founded inShanghai in 2004 by veterans of the US
biopharmaceutical industry, and is now a leading CRO company inChina. The
founding team has talent and track record in organic synthesis, medicinal
chemistry, drug design and discovery, process chemistry, cGMP API production,
in vitro/vivo PK research, and business and IP management. Sundia has
successfully worked with over 50 companies world-wide, and provides services
in custom synthesis, library production, lead optimization (PD and PK), scale
up, pre-clinical studies, cGMP API production and pharmaceutical development.
About HD BioSciences (http://www.hdbiosciences.com )
HD BioSciences, based inShanghai, is one of the leading biology CRO
companies inChina. The company is known for its expertise in assay
development, high-throughput screening (HTS), hit-to-lead solutions, high-
throughput compound profiling, and natural compound-based lead identification.
The company's proprietary assays and screening platforms give it a competitive
edge in drug lead discovery services and in providing value to its partners
and clients from pharmaceutical and biotech companies world-wide.
SOURCE Sundia Meditech
Copyright © 2008, PRNewswire
Copyright © 2008, NewsBlaze,
Daily News
Tags: ,CHM,HEA,MTC,BIO,ASI,LIC,NovaSecta-Chinese-CRO
_ _Is your favorite bookmark site missing?
Ask for it.